Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS)
约翰·霍普金斯大学 SARS-CoV-2 发病机制和免疫卓越中心 (JH-EPICS)
基本信息
- 批准号:10706725
- 负责人:
- 金额:$ 11.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAddressAffectAgeAntibodiesAntibody ResponseAntibody-mediated protectionAntigensBasic ScienceBiometryCOVID-19COVID-19 patientCOVID-19 severityCell surfaceCellsCessation of lifeClinicalClinical SciencesCollaborationsCommunicable DiseasesComplementComplexCoupledData AnalysesDevelopmentDiabetes MellitusDiseaseEnsureEnzyme-Linked Immunosorbent AssayEpidemiologic MonitoringEpidemiologyEthnic OriginEvaluationFlow CytometryFoundationsGenderGoalsHIVHealthHealthcare SystemsHeart DiseasesHumanImmuneImmune responseImmunityImmunoglobulin Class SwitchingImmunologyImmunomodulatorsInfantInfectionInflammasomeInflammatory ResponseInfrastructureInterdisciplinary StudyInternationalLeadershipMediatingMetabolicMethodsMissionModelingMonoclonal Antibody TherapyMyeloid-derived suppressor cellsOutcomePathogenesisPathologicPathologyPatientsPeripheral Blood Mononuclear CellPersonsPopulationProspective cohortProteinsProtocols documentationPublic HealthRaceReagentRegimenReportingResearchResearch ActivityResearch PersonnelResearch Project GrantsResourcesRespiratory Tract InfectionsRiskSARS-CoV-2 antibodySARS-CoV-2 immune responseSARS-CoV-2 immunitySARS-CoV-2 infectionSamplingScienceSerologySerology testSeverity of illnessSex DifferencesSolidStainsStatistical Data InterpretationStatistical ModelsSurrogate MarkersSymptomsT-LymphocyteTestingTherapeuticTrainingTranslational ResearchUrsidae FamilyVaccine DesignViralViral PathogenesisVirusage differenceantibody-dependent cell cytotoxicitybasebiosafety level 3 facilitycomorbidityexperimental studygender differenceinnate immune sensinginsightintersectionalitymaleneutralizing antibodynew therapeutic targetnovelnovel markerorgan transplant recipientpandemic diseaseracial differencerational designresponsesample fixationsevere COVID-19sexsingle cell analysistherapeutic evaluationtherapy developmentvaccine candidatevaccine developmentvaccine evaluationvirology
项目摘要
Johns Hopkins has broad expertise in the science of human health, with viral immunity, pathogenesis, epidemiology, biostatistics, and surveillance emerging as integral components of the multidisciplinary research mounted at Johns Hopkins during the current pandemic. We have operated a Serological Sciences Center of Excellence: the Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS). The overarching goal of JH-EPICS since 2020 with ongoing projects to distinguish immune responses that protect from those that cause pathology during infection and to analyze vaccine induced immune responses. We have resources and samples available to systematically evaluate innate, T cell, and antibody responses to SARS-CoV-2 in peripheral blood mononuclear cells and serological samples from COVID-19 vaccine recipients and patients sampled longitudinally. JH-EPICS contains three interconnecting Research Projects (RPs). RP1 focuses on innate immune sensing and activation of the human inflammasome by SARS-CoV-2, with evaluation of how anti-SARS-CoV-2 antibodies modulate innate sensing. RP2 uses traditional techniques to assess T cell responses, including ELISpot, and a novel flow-cytometry based platform that enables single cell analysis of cell surface markers combined with intracellular staining for proteins involved in metabolic programming. In RP3, the magnitude, duration, and class switching of SARS-CoV-2-specific antibody isotypes as well as virus-specific neutralizing antibody responses is analyzed and compared with non-neutralizing antibody functions, e.g., complement fixation and antibody-dependent cellular cytotoxicity, using a novel core set of serological assays. A centralized Virology Reagent Core provides antigen for ELISAs, reagents to identify virus-specific immune cell populations, inactivated SARS-CoV-2 viruses, methods for quantifying SARS-CoV-2, and access to biosafety level 3 facilities and training needed to perform any experiments involving live SARS-CoV-2. The Analysis Resource Core provides statistical modeling and analysis to frame and test hypotheses about the mechanisms mediating the severity of COVID-19 as well as the intersectionality of sex, gender, age, and racial differences in immune mechanisms of COVID-19 disease and vaccination. In concert with the trans-network collaborations, this research provides significant insights into pathologic immune responses to SARS-CoV-2 and elucidates mechanisms of immunity against SARS-CoV-2 infection and vaccination. By uncovering the correlates of protective immunity following boosting, JH-EPICS research will further enhance vaccine design and evaluation of vaccine candidates.
约翰·霍普金斯大学在人类健康科学方面拥有广泛的专业知识,病毒免疫、发病机制、流行病学、生物统计学和监测已成为约翰·霍普金斯大学在当前大流行期间开展的多学科研究的组成部分。我们运营着一个血清学科学卓越中心:约翰霍普金斯大学 SARS-CoV-2 发病机制和免疫卓越中心 (JH-EPICS)。自 2020 年以来,JH-EPICS 的总体目标是区分免疫反应,以防止感染过程中引起病理的免疫反应,并分析疫苗诱导的免疫反应。我们拥有可用的资源和样本,可系统评估外周血单核细胞以及纵向采样的 COVID-19 疫苗接种者和患者的血清学样本中对 SARS-CoV-2 的先天反应、T 细胞和抗体反应。 JH-EPICS 包含三个相互关联的研究项目 (RP)。 RP1 专注于先天免疫感应和 SARS-CoV-2 对人类炎症体的激活,并评估抗 SARS-CoV-2 抗体如何调节先天感应。 RP2 使用传统技术评估 T 细胞反应,包括 ELISpot 和基于新型流式细胞术的平台,该平台能够对细胞表面标记物进行单细胞分析,并结合对参与代谢编程的蛋白质进行细胞内染色。在 RP3 中,使用一套新颖的核心血清学检测方法,分析了 SARS-CoV-2 特异性抗体同种型以及病毒特异性中和抗体反应的幅度、持续时间和类别转换,并与非中和抗体功能(例如补体结合和抗体依赖性细胞毒性)进行比较。集中式病毒学试剂核心提供 ELISA 抗原、识别病毒特异性免疫细胞群的试剂、灭活的 SARS-CoV-2 病毒、量化 SARS-CoV-2 的方法,以及进行涉及活 SARS-CoV-2 的任何实验所需的生物安全 3 级设施和培训。分析资源核心提供统计建模和分析,以构建和测试有关调节 COVID-19 严重程度的机制的假设,以及性别、性别、年龄和种族差异在 COVID-19 疾病和疫苗接种免疫机制中的交叉性。与跨网络合作相结合,这项研究提供了对 SARS-CoV-2 病理免疫反应的重要见解,并阐明了针对 SARS-CoV-2 感染和疫苗接种的免疫机制。通过揭示加强免疫后保护性免疫的相关性,JH-EPICS 研究将进一步加强疫苗设计和候选疫苗的评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREA L COX其他文献
ANDREA L COX的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREA L COX', 18)}}的其他基金
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10614971 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10205729 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10205731 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10398149 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Immunologic and Metabolic Profiles of T cells that control diverse HCV infections
控制多种 HCV 感染的 T 细胞的免疫学和代谢特征
- 批准号:
10398150 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Sex, obesity, immunometabolism, and viral persistence in post-acute sequelae of SARS-CoV-2 infection
SARS-CoV-2 感染急性后遗症中的性别、肥胖、免疫代谢和病毒持续性
- 批准号:
10554731 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10398147 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10398148 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine
自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发
- 批准号:
10671902 - 财政年份:2021
- 资助金额:
$ 11.97万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 11.97万 - 项目类别:
Research Grant